STEPHEN GEORGE DILLY
CIK 1389147 · See Remarks · last filed 2026-06-18
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$10.97M
Companies
6
Total Filings
48
Lifetime Open-Market Net
-$21.65M
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| CDXS | See Remarks | 727,053 | $1.49 | $1.08M | -$151.3K | 11 | 2026-06-18 |
| Sierra Oncology, Inc. (SRRA) Delisted | CEO and President | 0 | $54.99 | $0 | $89.1K | 7 | 2022-07-01 |
| SANGAMO THERAPEUTICS, INC (SGMO) Delisted | Director | 15,000 | $0.18 | $2.7K | -$300.3K | 13 | 2020-06-03 |
| COLL | President and CEO | 370,297 | $26.71 | $9.89M | -$21.29M | 12 | 2018-06-13 |
| Aimmune Therapeutics, Inc. (AIMT) Delisted | See Remarks | 831,158 | — | — | $0 | 1 | 2016-02-26 |
| AVIGEN INC \DE (AVGN) Delisted | Director | — | — | — | $0 | 4 | 2009-12-21 |
Recent Filings · Page 4 of 5
48 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2017-09-27 | COLL | Mixed | −100,000 | -$2.50M | EDGAR |
| 2017-07-28 | COLL | Sell (S) | −50,000 | -$1.07M | EDGAR |
| 2017-06-27 | COLL | Sell (S) | −49,400 | -$998.6K | EDGAR |
| 2017-06-07 | SANGAMO THERAPEUTICS, INC (SGMO) Delisted | Grant (A) | — | $0 | EDGAR |
| 2017-05-12 | COLL | Sell (S) | −600 | -$12.1K | EDGAR |
| 2017-02-24 | COLL | Grant (A) | — | $0 | EDGAR |
| 2016-11-15 | COLL | Mixed | −50,000 | -$1.25M | EDGAR |
| 2016-06-15 | SANGAMO THERAPEUTICS, INC (SGMO) Delisted | Grant (A) | — | $0 | EDGAR |
| 2016-02-26 | Aimmune Therapeutics, Inc. (AIMT) Delisted | Grant (A) | — | $0 | EDGAR |
| 2015-06-24 | SANGAMO THERAPEUTICS, INC (SGMO) Delisted | Grant (A) | — | $0 | EDGAR |
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.